The aim of this study is to investigate the safety profile and establish a recommended dose (RD) for phase II of the antibody-cytokine fusion protein L19TNF in combination with the standard chemoradiotherapy TMZ in patients with newly diagnosed glioblastoma.
Aim of the study
We are conducting this study to evaluate the safety, tolerability, efficacy and optimal dose of the new drug L19TNF with potential anticancer activity plus standard radiotherapy and temozolomide in patients with newly diagnosed glioblastoma.
Who can take part?
Patients with glioblastoma
Procedure
First, your doctor will examine and question you in detail to determine whether you are suitable for participation in the study (screening). Every patient receives the recognized standard therapy for newly diagnosed glioblastoma. This consists of 6 weeks of chemoradiotherapy, during which radiotherapy and temozolomide are used. This is followed by a 4-week treatment break and a maintenance therapy in which only temozolomide is used.
Compensation
None
Original study name
Safety and efficacy of L19TNF plus temozolomide chemoradiotherapy in patients with newly diagnosed glioblastoma
BASEC number
2020-01699
Financial support from
Philogenic